Desktop Genetics develops cell therapies for the heart, and platelet therapies that aid with tissue regeneration.
Desktop Genetics helps scientists discover, understand and treat the root genetic causes of human diseases. Since 2012, Desktop Genetics has supported thousands of labs around the world with best-in-class CRISPR genome editing design and analysis technology, across basic research, drug discovery, translational research and IND-enabling studies.
At the core of Desktop’s products and services lies the DESKGEN AI. The DESKGEN AI is a machine-learning platform for designing CRISPR experiments with maximum efficiency while minimising unwanted side-effects (also known as ‘off-target’ effects). This platform is the result of 4 years of research and development, leveraging what the company believe to be one of the largest databases of empirical genome editing data in the world.
Desktop Genetics’ tools and technologies are used by t scientists in organisation around the world, including four of the top five blue chip pharmaceutical companies and world-renowned institutions such as the University College London Great Ormond Street Institute of Child Health, the Netherlands Cancer Institute, and the Copenhagen Center for Glycomics.
In June 2018 Desktop Genetics was acquired by Celixir plc, a pioneering company founded by Nobel laureate Sir Martin Evans and Ajan Reginald for the development of cell and gene therapies to treat incurable or poorly treated diseases.